FDA Awards Full Approval for LeqembiTM
On July 6, 2023, the U.S. Food and Drug Administration (FDA) announced full approval for LeqembiTM, the brand name for lecanemab (BAN-2401), for the treatment of Alzheimer’s disease. The availability of a therapy for early stages of the disease is a tremendous milestone for Alzheimer’s patients and caregivers. This breakthrough will spark important research into other therapeutic options.
2022 CureAlz Annual Report Now Available
The 2022 annual report for Cure Alzheimer’s Fund, detailing research investments and the record level of distribution to scientists, is now available online.
Please Consider Making a Donation
Today, more than 6 million people in the United States are living with a diagnosis of Alzheimer’s disease.
Your gifts have enabled Cure Alzheimer’s Fund to support researchers who are relentless in their desire to understand Alzheimer’s disease and develop a therapy. Because of you, they have made great progress. New information is emerging every day including the impact of genetics and lifestyle choices, and how the disease might be diagnosed early — when treatments could be most effective. There is great momentum in the field of Alzheimer’s disease, but so much more to learn and discover.
If you recently made a donation to Cure Alzheimer’s Fund, thank you. If not, please consider a gift today.
100% of your donation will go directly to research and contribute to progress so that we may realize a world without Alzheimer’s disease.